| Description | Zanamivir hydrate is neuraminidase inhibitors. It is used worldwide for the treatment and prophylaxis of influenza caused by influenza A and B viruses. |
| Synonyms | D01937, J1.917.534K |
| molecular weight | 350.328 |
| Molecular formula | C12H22N4O8 |
| CAS | 551942-41-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014 Apr 9;348:g2547. doi: 10.1136/bmj.g2547. Review. PubMed PMID: 24811412; PubMed Central PMCID: PMC3981976. 2. Pizzorno A, Abed Y, Rhéaume C, Boivin G. Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses. Antiviral Res. 2014 May;105:54-8. doi: 10.1016/j.antiviral.2014.02.017. Epub 2014 Feb 28. PubMed PMID: 24583158. 3. Chan-Tack KM, Kim C, Moruf A, Birnkrant DB. Clinical experience with intravenous zanamivir under an Emergency IND program in the United States (2011-2014). Antivir Ther. 2015;20(5):561-4. doi: 10.3851/IMP2944. Epub 2015 Feb 10. Review. PubMed PMID: 25667992. 4. Dunstan HJ, Mill AC, Stephens S, Yates LM, Thomas SH. Pregnancy outcome following maternal use of zanamivir or oseltamivir during the 2009 influenza A/H1N1 pandemic: a national prospective surveillance study. BJOG. 2014 Jun;121(7):901-6. doi: 10.1111/1471-0528.12640. Epub 2014 Mar 7. PubMed PMID: 24602087. |